Kyverna Therapeutics, Inc. Common Stock (KYTX) Stock
NASDAQ · KYTX
Key stats
- Market cap
- $316.64M
- Price / Earnings ratio
- -2.1x
- EPS (TTM)
- -$2.93
- Volume
- Loading
- 52-week high
- $13.67
- 52-week low
- $4.50
Source: third-party data provider, as of November 13, 2026
Compare with KYTX
Recent news

Stocktwits
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
KYTXSeptember 24, 2026
Stocktwits
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
KYTX

24/7 Wall Street
Kyverna Therapeutics Sinks 13%: Here's Why
KYTXJuly 10, 2026
24/7 Wall Street
Kyverna Therapeutics Sinks 13%: Here's Why
KYTX

The Motley Fool
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
KYTXJune 8, 2026
The Motley Fool
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
KYTX

Stocktwits
Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today
KYTXApril 22, 2026
Stocktwits
Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today
KYTX
Technical indicators
- RSI 14
- 39.89
- MACD 12/26/9
- -0.38
- EMA 9 of MACD
- -0.40
- MACD histogram
- 0.01
- SMA 50
- $6.35
- Price below SMA 50
- EMA 50
- $6.19
- Price below EMA 50
- SMA 200
- $7.92
- Price below SMA 200
- EMA 200
- $7.54
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
8M6M3M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
366M241M121M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-161.3M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Stocktwits
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
KYTXSeptember 24, 2026
Stocktwits
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
KYTX

24/7 Wall Street
Kyverna Therapeutics Sinks 13%: Here's Why
KYTXJuly 10, 2026
24/7 Wall Street
Kyverna Therapeutics Sinks 13%: Here's Why
KYTX

The Motley Fool
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
KYTXJune 8, 2026
The Motley Fool
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
KYTX

Stocktwits
Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today
KYTXApril 22, 2026
Stocktwits
Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today
KYTX

Stocktwits
KYTX Stock Soars After Hours: What’s Driving The Rally?
KYTXApril 22, 2026
Stocktwits
KYTX Stock Soars After Hours: What’s Driving The Rally?
KYTX

24/7 Wall Street
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
KYTXFebruary 16, 2026
24/7 Wall Street
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
KYTX

Zacks Investment Research
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTXDecember 30, 2025
Zacks Investment Research
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX

Zacks Investment Research
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
KYTXDecember 16, 2025
Zacks Investment Research
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
KYTX

Zacks Investment Research
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
KYTXDecember 16, 2025
Zacks Investment Research
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
KYTX

Stocktwits
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome?
KYTXDecember 15, 2025
Stocktwits
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome?
KYTX
About Kyverna Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees149
CEOMr. Warner Biddle
IPO DateFeb 8, 2024
HeadquartersEmeryVille, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Warner Biddle | CEO & Director | 1967 |
| Ms. Christi L. Shaw | Executive Chairperson | 1967 |
| Mr. Gregory Martini | Chief Financial Officer | 1989 |
| Dr. Naji H. Gehchan M.B.A., M.D. | Chief Medical & Development Officer | 1982 |
| Dr. Tom Van Blarcom Ph.D. | Senior VP & Head of Research | — |
| Mr. Mayo Pujols | Chief Technology Officer | 1970 |
| Ms. Jessica Serra | Head of Investor Relations | — |
| Mr. Ritesh Srivastava | Chief Legal & Compliance Officer | — |
| Ms. Cara Bauer Ph.D. | Chief Human Resources Officer | — |
| Ms. Tracy Rossin | Senior Vice President of Corporate Affairs | 1977 |
Fundamentals
Valuation
Price-to-book value1.90
Profitability
Return on Equity-82.00%
Return on Assets-64.00%
EBITDA$-146.83M
Trading
Average volume843,667
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 39.89
- MACD 12/26/9
- -0.38
- EMA 9 of MACD
- -0.40
- MACD histogram
- 0.01
- SMA 50
- $6.35
- Price below SMA 50
- EMA 50
- $6.19
- Price below EMA 50
- SMA 200
- $7.92
- Price below SMA 200
- EMA 200
- $7.54
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -9.4 | -10.5 | -32.8 | -24.6 | -42.6 | +10.9 | +2.3 | -33.6 | +1.1 | +18.0 | -42.4 | |
| 2025 | -17.3 | -8.4 | -25.5 | +16.7 | +14.9 | +15.8 | +28.9 | +7.8 | +67.1 | +16.8 | +11.5 | +39.7 |
| 2026 | -8.7 | -1.4 | +1.4 | +0.3 | -3.9 | +8.4 | -13.5 | +12.9 | -18.6 | -13.0 | -1.9 |
Compare stocks
Market cap
$316.64M
-
-
-
Price / Earnings ratio
-2.10
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
843,667
-
-
-
Earnings per share
$-2.93
-
-
-



